1-12 of 12
Carol O'Hear
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Magrolimab in Combination with Rituximab + Chemotherapy in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Joseph Maakaron, Adam S. Asch, Leslie L. Popplewell, Graham P. Collins, Ian W. Flinn, Nilanjan Ghosh, Colin Keane, Matthew Ku, Amitkumar Mehta, Mark Roschewski, Carol O'Hear, Xuehan Ren, Bertha Villa, Indu Lal, Sonali M. Smith, Ranjana H. Advani
Journal: Blood
Blood (2022) 140 (Supplement 1): 3728–3730.
https://doi.org/10.1182/blood-2022-167772
Published: 2022
Journal Articles

Subcutaneous (SC) Administration of Mosunetuzumab with Cycle 1 Step-up Dosing Is Tolerable and Active in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphomas (R/R B-NHL): Initial Results from a Phase I/II Study

Nancy L. Bartlett, Pratyush Giri, L. Elizabeth Budde, Stephen J. Schuster, Sarit Assouline, Matthew J. Matasar, Sung-Soo Yoon, Miguel Canales, Norma C. Gutierrez, Keith Fay, Chan-Yoon Cheah, Paula Marlton, Volker Wiebking, Shen Yin, Iris To, Chi-Chung Li, Huang Huang, Mingzhu Zhou, Elicia Penuel, Carol O'Hear, Laurie H. Sehn
Journal: Blood
Blood (2021) 138 (Supplement 1): 3573.
https://doi.org/10.1182/blood-2021-147937
Published: 2021
Journal Articles

Mosunetuzumab in Combination with Lenalidomide Has a Manageable Safety Profile and Encouraging Activity in Patients with Relapsed/Refractory Follicular Lymphoma: Initial Results from a Phase Ib Study

Franck Morschhauser, Mark Bishton, Toby A. Eyre, Emmanuel Bachy, Guillaume Cartron, Loïc Ysebaert, Sabela Bobillo, Norma C. Gutierrez, L. Elizabeth Budde, Christopher P. Fox, Andrea Knapp, Manejeh Yaqub, Michael C. Wei, Carol O'Hear, Haocheng Li, Enkhtsetseg Purev, William Townsend
Journal: Blood
Blood (2021) 138 (Supplement 1): 129.
https://doi.org/10.1182/blood-2021-145694
Published: 2021
Journal Articles

Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study

L. Elizabeth Budde, Laurie H. Sehn, Matthew J. Matasar, Stephen J. Schuster, Sarit Assouline, Pratyush Giri, John Kuruvilla, Miguel Canales, Sascha Dietrich, Keith Fay, Matthew Ku, Loretta Nastoupil, Michael C. Wei, Shen Yin, Michelle Y. Doral, Chi-Chung Li, Huang Huang, Raluca Negricea, Elicia Penuel, Carol O'Hear, Nancy L. Bartlett
Journal: Blood
Blood (2021) 138 (Supplement 1): 127.
https://doi.org/10.1182/blood-2021-145872
Published: 2021
Journal Articles

Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts

Matthew J Matasar, MD, Chan Yoon Cheah, MBBS, Dok Hyun Yoon, Sarit E Assouline, MD MSc, Nancy L. Bartlett, MD, Matthew Ku, Pratyush Giri, Anna Johnston, MBBS (Hons 1), FRACP, FRCPA, Ian W. Flinn, MD PhD, Andre H. Goy, MD, Dimitrios Tzachanis, MD PhD, Carol O'Hear, Shen Yin, Iris To, Kati Sarouei, Chi-Chung Li, Brendan C. Bender, Elicia M. Penuel, Huang Huang, L. Elizabeth Budde
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–46.
https://doi.org/10.1182/blood-2020-135818
Published: 2020
Journal Articles

Unmet Medical Need Among Elderly Patients with Previously Untreated DLBCL Characterized Using Real-World Data in the United States

Ashwini Shewade, Adam J Olszewski, MD, Nelson Pace, Andy Surinach, MPH, Gila Sellam, Lars Mueller, Carol O'Hear
Journal: Blood
Blood (2020) 136 (Supplement 1): 6–8.
https://doi.org/10.1182/blood-2020-136271
Published: 2020
Journal Articles

Mosunetuzumab, a Novel CD20/CD3 Bispecific Antibody, in Combination with CHOP Confers High Response Rates in Patients with Diffuse Large B-Cell Lymphoma

Tycel J. Phillips, MD, Adam J Olszewski, MD, Javier Munoz, MD, Tae Min Kim, MD PhD, Dok Hyun Yoon, Richard Greil, MD, Jason Westin, MD, Ulrich Jaeger, Miguel Canales, Cindy Chen, Betsy Althaus, Carol O'Hear, Raluca Negricea, Yuying Xie, Ronald McCord, Enkhtsetseg Purev, Anusha Vallurupalli
Journal: Blood
Blood (2020) 136 (Supplement 1): 37–38.
https://doi.org/10.1182/blood-2020-136295
Published: 2020
Journal Articles

Single-Agent Mosunetuzumab Is a Promising Safe and Efficacious Chemotherapy-Free Regimen for Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Adam J Olszewski, MD, Abraham Avigdor, MD, Sunil Babu, Itai Levi, MD, Uri Abadi, Houston Holmes, Matthew McKinney, Ron McCord, Yuying Xie, Cindy Chen, Kati Sarouei, Naseer Qayum, Carol O'Hear, Gila Sellam, Herbert Eradat
Journal: Blood
Blood (2020) 136 (Supplement 1): 43–45.
https://doi.org/10.1182/blood-2020-136255
Published: 2020
Journal Articles

Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines

Stephen J Schuster, MD, Nancy L Bartlett, MD, Sarit Assouline, MD, Sung-Soo Yoon, MD PhD, Francesc Bosch, MD PhD, Laurie H Sehn, MD, Chan Y. Cheah, Mazyar Shadman, MD MPH, Gareth P Gregory, MBBS (Hons), PhD FRACP, FRCPA, Matthew Ku, MBBS, FRACP, FRCPA, PhD, Michael C Wei, MD PhD, Shen Yin, PhD, Antonia Kwan, MD PhD MRCPCH, Kasra Yousefi, MSc, Genevive Hernandez, PhD, Chi-Chung Li, PhD, Carol O'Hear, MD PhD, Lihua E Budde, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 6.
https://doi.org/10.1182/blood-2019-123742
Published: 2019
Journal Articles

Exposure-Response Analyses Indicate a Promising Benefit/Risk Profile of Mosunetuzumab in Relapsed and Refractory Non-Hodgkin Lymphoma

Chi-Chung Li, PhD, Brendan Bender, PhD, Shen Yin, PhD, Zao Li, PhD, Cindy Zhang, MS, Genevive Hernandez, PhD, Antonia Kwan, MD PhD MRCPCH, Laura Sun, PhD, Joanne I Adamkewicz, PhD, Hong Wang, MD PhD DABT, Natalie Dimier, PhD, Sue-Zen Lim, BPharm, Carol O'Hear, MD PhD, Laurie H Sehn, MD, Ian W. Flinn, MD PhD, Sung-Soo Yoon, MD PhD, Lihua E Budde, MD PhD, Chunze Li, PhD, Michael C Wei, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1285.
https://doi.org/10.1182/blood-2019-123961
Published: 2019
Journal Articles

Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma

Genevive Hernandez, PhD, Ling-Yuh Huw, PhD, Anton Belousov, PhD, Deanna Wilson, MS, Hartmut Koeppen, MD PhD, Ron McCord, PhD, Kun Peng, PhD, Nancy L Bartlett, MD, Lihua E Budde, MD PhD, Sarit Assouline, MD, Loretta J. Nastoupil, MD MSc, Dok Hyun Yoon, MD PhD, Matthew J Matasar, MD, Brendan Bender, PhD, Antonia Kwan, MD PhD MRCPCH, Chi-Chung Li, PhD, Carol O'Hear, MD PhD, Shen Yin, PhD, Michael C Wei, MD PhD, Joanne I Adamkewicz, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1585.
https://doi.org/10.1182/blood-2019-123933
Published: 2019
Journal Articles

An Individualized Risk Mitigation Approach for Safety: Experience from the Mosunetuzumab (CD20/CD3 Bispecific Antibody) Development Program in Relation to Neurotoxicity Risk

Catherine Diefenbach, MD, Sarit Assouline, MD, Francesc Bosch, MD PhD, Chan Y. Cheah, Won Seog Kim, MD PhD, Matthew J Matasar, MD, Carlos Panizo, MD PhD, Dok Hyun Yoon, MD PhD, Brendan Bender, PhD, Genevive Hernandez, PhD, Chi-Chung Li, PhD, Bruce McCall, MD, Carol O'Hear, MD PhD, Michael C Wei, MD PhD, Shen Yin, PhD, Kasra Yousefi, MSc, Antonia Kwan, MD PhD MRCPCH, Loretta J. Nastoupil, MD MSc
Journal: Blood
Blood (2019) 134 (Supplement_1): 4728.
https://doi.org/10.1182/blood-2019-123757
Published: 2019